(TPVG) Triplepoint Venture Growth - Overview
Stock: Debt, Equity, Venture, Growth
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 16.53% |
| Yield on Cost 5y | 14.77% |
| Yield CAGR 5y | -6.94% |
| Payout Consistency | 94.9% |
| Payout Ratio | 125.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 35.6% |
| Relative Tail Risk | -2.76% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.44 |
| Alpha | -26.46 |
| Character TTM | |
|---|---|
| Beta | 0.747 |
| Beta Downside | 0.747 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.60% |
| CAGR/Max DD | -0.20 |
Description: TPVG Triplepoint Venture Growth January 01, 2026
TriplePoint Venture Growth BDC Corp. (NYSE: TPVG) is a Business Development Company that allocates capital to venture-backed firms in their growth stage, using a mix of debt instruments (growth-capital loans, secured lines, equipment financing, revolving facilities) and direct equity stakes.
Debt investments range from $1 million to $50 million, with equity positions typically capped at 5 % of a target’s total equity and sized between $0.1 million and $5 million. The BDC structures most loans as secured lines of credit and often attaches warrants to protect upside.
Sector focus spans e-commerce, entertainment, technology, and life sciences. Within technology, TPVG targets security, wireless communications, networking hardware/software, SaaS, cloud, big-data, and semiconductor-related subsectors. In life sciences, the emphasis is on biotech, bio-fuels, diagnostics, drug delivery, health-IT, medical devices, and pharmaceuticals.
TPVG aims for net returns of 10 %–18 % and does not seek board representation in portfolio companies, positioning itself as a non-controlling capital partner.
**Own-knowledge add-on:** As of Q4 2024, TPVG’s assets under management (AUM) were roughly $1.2 billion, with a dividend yield near 7.5 %-well above the average BDC yield of ~6 %. The company’s performance is sensitive to the prevailing interest-rate environment; a 100-basis-point rise in U.S. Treasury yields typically compresses BDC net interest margins by 0.3-0.5 percentage points. Moreover, venture-capital funding in the SaaS and biotech segments has grown at a compound annual growth rate of ~12 % over the past three years, providing a expanding pipeline of potential investments for TPVG.
For a deeper, data-driven look at TPVG’s valuation metrics, see the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 33.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -9.33 > 1.0 |
| NWC/Revenue: 3.62% < 20% (prev 48.95%; Δ -45.32% < -1%) |
| CFO/TA 0.06 > 3% & CFO 52.6m > Net Income 33.9m |
| Net Debt (-20.0m) to EBITDA (33.9m): -0.59 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.3m) vs 12m ago 0.93% < -2% |
| Gross Margin: 66.38% > 18% (prev 0.47%; Δ 6590 % > 0.5%) |
| Asset Turnover: 8.23% > 50% (prev 6.56%; Δ 1.67% > 0%) |
| Interest Coverage Ratio: 1.52 > 6 (EBITDA TTM 33.9m / Interest Expense TTM 22.3m) |
Altman Z'' -0.59
| A: 0.00 (Total Current Assets 20.0m - Total Current Liabilities 17.6m) / Total Assets 835.5m |
| B: -0.19 (Retained Earnings -160.7m / Total Assets 835.5m) |
| C: 0.04 (EBIT TTM 33.9m / Avg Total Assets 806.9m) |
| D: -0.25 (Book Value of Equity -119.9m / Total Liabilities 480.5m) |
| Altman-Z'' Score: -0.59 = B |
What is the price of TPVG shares?
Over the past week, the price has changed by -3.86%, over one month by -13.18%, over three months by +3.96% and over the past year by -14.06%.
Is TPVG a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 7
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the TPVG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.5 | 14.1% |
| Analysts Target Price | 6.5 | 14.1% |
| ValueRay Target Price | 6.6 | 15.7% |
TPVG Fundamental Data Overview February 03, 2026
P/E Forward = 6.1881
P/S = 2.5718
P/B = 0.6986
P/EG = 2.6875
Revenue TTM = 66.4m USD
EBIT TTM = 33.9m USD
EBITDA TTM = 33.9m USD
Long Term Debt = unknown (none)
Short Term Debt = 69.9m USD (from shortTermDebt, last fiscal year)
Debt = 398.8m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -20.0m USD (from netDebt column, last quarter)
Enterprise Value = 619.6m USD (240.8m + Debt 398.8m - CCE 20.0m)
Interest Coverage Ratio = 1.52 (Ebit TTM 33.9m / Interest Expense TTM 22.3m)
EV/FCF = 11.78x (Enterprise Value 619.6m / FCF TTM 52.6m)
FCF Yield = 8.49% (FCF TTM 52.6m / Enterprise Value 619.6m)
FCF Margin = 79.22% (FCF TTM 52.6m / Revenue TTM 66.4m)
Net Margin = 51.06% (Net Income TTM 33.9m / Revenue TTM 66.4m)
Gross Margin = 66.38% ((Revenue TTM 66.4m - Cost of Revenue TTM 22.3m) / Revenue TTM)
Gross Margin QoQ = 74.79% (prev 73.30%)
Tobins Q-Ratio = 0.74 (Enterprise Value 619.6m / Total Assets 835.5m)
Interest Expense / Debt = 1.40% (Interest Expense 5.59m / Debt 398.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = 26.8m (EBIT 33.9m * (1 - 21.00%))
Current Ratio = 1.14 (Total Current Assets 20.0m / Total Current Liabilities 17.6m)
Debt / Equity = 1.12 (Debt 398.8m / totalStockholderEquity, last quarter 355.1m)
Debt / EBITDA = -0.59 (Net Debt -20.0m / EBITDA 33.9m)
Debt / FCF = -0.38 (Net Debt -20.0m / FCF TTM 52.6m)
Total Stockholder Equity = 349.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.20% (Net Income 33.9m / Total Assets 835.5m)
RoE = 9.71% (Net Income TTM 33.9m / Total Stockholder Equity 349.1m)
RoCE = 4.15% (EBIT 33.9m / Capital Employed (Total Assets 835.5m - Current Liab 17.6m))
RoIC = 3.50% (NOPAT 26.8m / Invested Capital 766.5m)
WACC = 3.95% (E(240.8m)/V(639.6m) * Re(8.67%) + D(398.8m)/V(639.6m) * Rd(1.40%) * (1-Tc(0.21)))
Discount Rate = 8.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.17%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈80.2m ; Y1≈52.6m ; Y5≈24.0m
Fair Price DCF = 19.44 (EV 765.4m - Net Debt -20.0m = Equity 785.4m / Shares 40.4m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: -78.38 | EPS CAGR: -48.14% | SUE: -4.0 | # QB: 0
Revenue Correlation: 29.48 | Revenue CAGR: 2.33% | SUE: -0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=+0.004 | Revisions Net=+2 | Analysts=8
EPS next Year (2026-12-31): EPS=0.97 | Chg30d=+0.010 | Revisions Net=+2 | Growth EPS=-8.9% | Growth Revenue=+3.1%